BFM
NAGE

Boothbay Fund Management’s Niagen Bioscience NAGE Stock Holding History

Boothbay Fund Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,849
Closed -$133K – 2563
2025
Q4 		$133K Buy
+20,849
New +$145K ﹤0.01% 1712
2024
Q1 		– Sell
-149,035
Closed -$213K – 1986
2023
Q4 		$213K Buy
149,035
+10,122
+7% +$14.1K 0.01% 1311
2023
Q3 		$203K Buy
+138,913
New +$217K ﹤0.01% 1432
2019
Q2 		– Sell
-31,578
Closed -$132K – 923
2019
Q1 		$132K Buy
31,578
+14,058
+80% +$50.7K 0.01% 639
2018
Q4 		$60K Buy
+17,520
New +$60.9K 0.01% 582

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boothbay Fund Management's NAGE Position: Q1 2026 in Review

Boothbay Fund Management sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 20,849 shares — an estimated $133K sold.

Boothbay Fund Management first reported a position in NAGE in Q4 2018 and held it in 5 quarters. The position peaked at $213K in Q4 2023. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Boothbay Fund Management reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 20,849 Niagen Bioscience shares in Q1 2026, an estimated $133K.
  • Boothbay Fund Management first reported a position in Niagen Bioscience in Q4 2018 and held it in 5 quarters.
  • Boothbay Fund Management's Niagen Bioscience position peaked at $213K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.